Mylan gets DCGI nod for anti-tuberculosis drug Pretomanid for conditional access

The Drug Controller General of India (DCGI) has approved Pretomanid for conditional access under the National Tuberculosis Elimination Program (NTEP), Mylan said in a statement. Through the conditional access approval from DCGI, Mylan will initially make its Pretomanid available in India through a donation of 400 treatment courses to the NTEP, it added.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3horOKp
via IFTTT